Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 138 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: T regulatory cells Clear all
Recruiting Phase 2 Interventional

A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma

NCT06843434
View directory record Official record
Conditions
Microsatellite Stable Rectal Carcinoma, Locally Advanced Rectal Adenocarcinoma
Interventions
Balstilimab, Botensilimab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 22, 2026, 1:24 AM EDT
Suspended Phase 1 Interventional

Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

NCT05993611
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder, Steroid Refractory Graft Versus Host Disease
Interventions
Biopsy, Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography, Echocardiography, Electronic Health Record Review, Leukapheresis, Lumbar Puncture, Magnetic Resonance Imaging, Quality-of-Life Assessment, Tafasitamab, X-Ray Imaging
Procedure · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 22, 2026, 1:24 AM EDT
Completed No phase listed Observational

Effect of Denileukin Diftitox on Immune System in CTCL Patients

NCT00254332
View directory record Official record
Conditions
Cutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 22, 2026, 1:24 AM EDT
Completed Phase 1 Interventional

Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia

NCT00626483
View directory record Official record
Conditions
Malignant Neoplasms Brain
Interventions
RNA-loaded dendritic cell vaccine, basiliximab
Biological · Drug
Lead sponsor
Gary Archer Ph.D.
Other
Eligibility
18 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 22, 2026, 1:24 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors

NCT05200559
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Pembrolizumab, E7777
Drug
Lead sponsor
Alexander B Olawaiye, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 22, 2026, 1:24 AM EDT
Completed No phase listed Observational Results available

Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease

NCT02194439
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 22, 2026, 1:24 AM EDT
Completed Phase 2 Interventional Results available

RFT-5-dgA in Patients With Metastatic Melanoma

NCT00314093
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
RFT5pdgA
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 22, 2026, 1:24 AM EDT
Terminated Phase 2 Interventional

Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer

NCT00440973
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Bevacizumab, Interleukin-2
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 22, 2026, 1:24 AM EDT
Recruiting Phase 2 Interventional

REgulatory T Cell Therapy to Achieve Immunosuppression REduction

NCT06552169
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI
Drug · Biological
Lead sponsor
Singulera Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Phoenix, Arizona • Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 22, 2026, 1:24 AM EDT
Withdrawn Not applicable Interventional

Infliximab, Regulatory T Cells, IL2 and Crohn's Disease

NCT01266785
View directory record Official record
Conditions
Crohn's Disease
Interventions
Infliximab
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 22, 2026, 1:24 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency

NCT03733067
View directory record Official record
Conditions
CTLA4 Haploinsufficency, Chronic Cytopenia
Interventions
abatacept, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 22, 2026, 1:24 AM EDT
Recruiting Phase 1 Interventional

Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

NCT05423691
View directory record Official record
Conditions
Myelofibrosis
Interventions
CK0804
Drug
Lead sponsor
Cellenkos, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Sacramento, California • New York, New York • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 1:24 AM EDT
Recruiting Phase 1 Interventional

TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation

NCT03943238
View directory record Official record
Conditions
Living Donor Kidney Transplantation
Interventions
Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
2
States / cities
Palo Alto, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 22, 2026, 1:24 AM EDT
Completed Phase 1 Interventional

Trial of Adoptive Immunotherapy With TRACT to Prevent Rejection in Living Donor Kidney Transplant Recipients

NCT02145325
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Expanded Tregs
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 22, 2026, 1:24 AM EDT
Recruiting No phase listed Observational

Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection

NCT05084768
View directory record Official record
Conditions
Acute Rejection of Renal Transplant, Graft Failure
Interventions
Donor-derived cell-free DNA
Diagnostic Test
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 22, 2026, 1:24 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells

NCT01050764
View directory record Official record
Conditions
Leukemia, Acute, Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Interventions
Regulatory T-cells, Conventional T-cells, Melphalan, Thiotepa, Fludarabine, Anti-thymocyte globulin, rabbit, CliniMACS CD34 Reagent System
Drug · Device
Lead sponsor
Everett Meyer
Other
Eligibility
Up to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 22, 2026, 1:24 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL

NCT05114837
View directory record Official record
Conditions
Lymphoma Leukemia
Interventions
allogeneic CAR19 regulatory T cells (CAR19-tTreg), Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 22, 2026, 1:24 AM EDT
Terminated Phase 2 Interventional Results available

Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox

NCT02009384
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Ipilimumab
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 22, 2026, 1:24 AM EDT
Completed Phase 2 Interventional Results available

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

NCT03927105
View directory record Official record
Conditions
Peripheral T Cell Lymphoma
Interventions
Nivolumab, cabiralizumab
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Ann Arbor, Michigan • Columbus, Ohio • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 22, 2026, 1:24 AM EDT
Terminated Phase 1 Interventional

Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

NCT00725062
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
CD4+CD25+ regulatory T cells, allogeneic hematopoietic stem cell transplantation
Biological · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 22, 2026, 1:24 AM EDT
Completed Phase 1 Interventional

Infusion of T-Regulatory Cells in Kidney Transplant Recipients (The ONE Study)

NCT02091232
View directory record Official record
Conditions
Kidney Failure, Kidney Transplant
Interventions
T Regulatory Cell Infusion
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 22, 2026, 1:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease

NCT01795573
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Cultured Treg cells
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 22, 2026, 1:24 AM EDT
Completed Phase 1 Interventional

Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer

NCT00128622
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
denileukin diftitox, recombinant fowlpox-CEA(6D)/TRICOM vaccine, therapeutic autologous dendritic cells
Biological
Lead sponsor
H. Kim Lyerly
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Oct 22, 2026, 1:24 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

NCT05088356
View directory record Official record
Conditions
Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
Interventions
Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Melphalan, CliniMACS CD34 Reagent System, Tacrolimus, Cyclophosphamide, Plerixafor, Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent, Thiotepa, Mycophenolate Mofetil (MMF), Ruxolitinib, Sirolimus
Drug · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 22, 2026, 1:24 AM EDT